Health-Related Quality of Life in Non–Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials
- 1 August 2003
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2982-2992
Abstract
Purpose: Non–small-cell lung cancer (NSCLC), a leading cause of cancer-related deaths in both developed and developing countries, heavily impacts patient health-related quality of life (HRQOL). Although recent research has found many positive and significant steps in randomized controlled trials (RCTs) in which HRQOL has been used as an outcome, questions remain regarding methodologic quality and impact value of HRQOL outcome assessments in some RCTs. To date, no detailed systematic review exists of HRQOL methodology in NSCLC RCTs.Keywords
This publication has 55 references indexed in Scilit:
- Disclosure of financial competing interests in randomised controlled trials: cross sectional reviewBMJ, 2003
- Health related quality of life in prostate carcinoma patientsCancer, 2003
- Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?The Lancet Oncology, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Investigating and dealing with publication and other biases in meta-analysisBMJ, 2001
- Assessing the quality of controlled clinical trialsBMJ, 2001
- A Systematic Overview of Chemotherapy Effects in Non-Small Cell Lung CancerActa Oncologica, 2001
- Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancerLung Cancer, 1999
- Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance statusClinical Oncology, 1996
- Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective studyCancer, 1989